Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02)

Antibody Internalization Detection Reagent (IGG-PZF2001) monitors endocytosis in live cells
製品番号/仕様
価格
Availability
数量
DM4-MY2519a-100ug
$315.00
In Stock - Delivery in 2-3 business days
DM4-MY2519a-1mg (500ug X 2)
$1,890.00
In Stock - Delivery in 2 weeks
DM4-MY2519a
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Chimeric Monoclonal Anti-DM-4 Antibody, Rabbit IgG (M1H02) is recombinantly expressed in HEK293. It consists of rabbit variable regions genetically fused to rabbit IgG constant domains.

Antibody Type

Recombinant Monoclonal

Clone

M1H02

Isotype

Rabbit IgG, Kappa

Host Species

Rabbit

Immunogen

DM-4-BSA

Specificity

Specifically recognizes the target DM-1 & DM-4.

Application
Application
Recommended Use / Performance
ELISA
0.2-2 μg/mL
Purification

Protein A purified.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

バックグランド

DM4 (also known as ravtansine or soravtansine) is a maytansinoid derivative that serves as a potent cytotoxic payload in antibody-drug conjugates (ADCs). It functions by inhibiting tubulin polymerization, arresting cell division, and inducing apoptosis in tumor cells. Structurally modified from DM1, DM4 enhances conjugation compatibility with linkers and has been used in several clinical ADC drugs, including mirvetuximab soravtansine for ovarian cancer treatment.